Neuroscience
Placebo
100%
Emission Tomography
75%
Working Memory
75%
Tetrahydrocannabinol
75%
Dopamine Release
75%
Metacognition
75%
Amisulpride
56%
N-Back
56%
Risperidone
37%
Schizotypal Personality Disorder
37%
Hallucination
37%
Cholinergic
18%
Cognitive Process
18%
Psychoactive Drug
18%
Negative Syndrome
16%
Psychotomimetic
16%
Positive Syndrome
16%
Occipital Lobe
8%
Putamen
8%
Striatum
8%
Iodine-123
8%
Iodobenzamide
8%
Medicine and Dentistry
Schizotypy
75%
At Risk Mental State
75%
Metacognition
75%
Volunteer
56%
General Health Questionnaire
37%
Hallucination
37%
Schizotypal Personality Disorder
18%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo-Controlled Study
75%
Biological Marker
75%
Amisulpride
56%
Risperidone
37%
Normal Human
18%
Clinical Trial
18%
Cholinergic Receptor Stimulating Agent
18%
Schizotypal Personality Disorder
18%
Psychotropic Agent
18%
Placebo
18%
Iodobenzamide
8%